Head & Neck Cancers

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing over the last few decades, mostly due to HPV, which is now associated with the majority of newly diagnosed cases of OPSCC.

A growing understanding of the biological pathways at work in the development of oral mucositis in patients treated with cytotoxic cancer therapies has helped spur interest in steering symptom management away from "institutional folklore" rinses and anecdotal approaches toward evidence-based strategies

Anthony J. Cmelak, MD, professor, Radiation Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of ECOG1308, a study that evaluated reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response to induction chemotherapy.

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the safety profile of lenvatinib as seen in the phase III SELECT trial, which analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer.

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the rationale of the Active8 study.